Amoy Diagnostics (“AmoyDx”) successfully hosted its 2024 Distributors Annual Meeting in the dynamic city of Düsseldorf, Germany, bringing together distribution partners from across the globe for a day of insightful discussions and collaborative knowledge sharing focused on advancing oncology diagnostics.
This year's meeting centered on the evolving needs of oncology diagnostic testing, highlighting the critical role of multi-institutional collaboration in ensuring that high-quality, scientifically robust tests are accessible to patients worldwide. AmoyDx emphasized its commitment to decentralised healthcare solutions, including the deployment of locally based field engineers, to ensure that life-saving diagnostic tests are available in every hospital, regardless of location.
In addition to fostering valuable partnerships, the meeting served as an opportunity to celebrate key milestones in 2024, including the publication of new data, the approval of 11 companion diagnostics, and the continued expansion of AmoyDx's global distribution network. These accomplishments underscore the company's ongoing success and unwavering dedication to advancing precision medicine for cancer patients worldwide.
The event also featured valuable insights from esteemed guest speakers Dr. Pantelis, Dr. Boris, and Jasmine Lee, who shared their expertise on the impact of AmoyDx's innovative solutions in oncology diagnostics.
AmoyDx extends heartfelt gratitude to all attendees, speakers, and distributors for their contributions, which made the 2024 Distributors Annual Meeting a resounding success. As we look to the future, AmoyDx remains committed to driving impactful change in precision oncology and diagnostics, working hand-in-hand with partners to shape a brighter, more connected future in healthcare.
This year's meeting centered on the evolving needs of oncology diagnostic testing, highlighting the critical role of multi-institutional collaboration in ensuring that high-quality, scientifically robust tests are accessible to patients worldwide. AmoyDx emphasized its commitment to decentralised healthcare solutions, including the deployment of locally based field engineers, to ensure that life-saving diagnostic tests are available in every hospital, regardless of location.
In addition to fostering valuable partnerships, the meeting served as an opportunity to celebrate key milestones in 2024, including the publication of new data, the approval of 11 companion diagnostics, and the continued expansion of AmoyDx's global distribution network. These accomplishments underscore the company's ongoing success and unwavering dedication to advancing precision medicine for cancer patients worldwide.
The event also featured valuable insights from esteemed guest speakers Dr. Pantelis, Dr. Boris, and Jasmine Lee, who shared their expertise on the impact of AmoyDx's innovative solutions in oncology diagnostics.
AmoyDx extends heartfelt gratitude to all attendees, speakers, and distributors for their contributions, which made the 2024 Distributors Annual Meeting a resounding success. As we look to the future, AmoyDx remains committed to driving impactful change in precision oncology and diagnostics, working hand-in-hand with partners to shape a brighter, more connected future in healthcare.
AmoyDx® HRD Complete Panel Enters China NMPA’s Special Review Procedures for Innovative Medical Devices
Next
Subscribe
to our
newsletter